

# STUDIES IVERMECTINE

## Preprint studies

Afsar, N. Ivermectin Use Associated with Reduced Duration of COVID-19 Febrile Illness in a Community Setting [https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3734478](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3734478)

Aguirre-Chang, G. et al. Post-Acute or Prolonged COVID-19 Treatment with Ivermectin for Patients with Persistent, or Post-Acute Symptoms

[https://www.researchgate.net/publication/344318845\\_POST-ACUTE\\_OR\\_PROLONGED\\_COVID-19\\_IVERMECTIN\\_TREATMENT\\_FOR\\_PATIENTS\\_WITH\\_PERSISTENT\\_SYMPTOMS\\_OR\\_POST-ACUTE](https://www.researchgate.net/publication/344318845_POST-ACUTE_OR_PROLONGED_COVID-19_IVERMECTIN_TREATMENT_FOR_PATIENTS_WITH_PERSISTENT_SYMPTOMS_OR_POST-ACUTE)

Aguirre-Chang, G. & A. Figueredo, COVID-19: Pre-exposure Prophylaxis with Ivermectin for exposed people.

[https://www.researchgate.net/publication/343650306\\_COVID-19\\_Pre-exposure\\_Prophylaxis\\_with\\_Ivermectin\\_for\\_exposed\\_people](https://www.researchgate.net/publication/343650306_COVID-19_Pre-exposure_Prophylaxis_with_Ivermectin_for_exposed_people)

Aguirre-Chang, G. et al. COVID-19 Persistent: Treatment with Ivermectin and Acetylsalicylic acid of patients with the persistent syndrome of anosmia or hyposmia

[https://www.researchgate.net/publication/344468089\\_COVID-19\\_Persistent\\_Treatment\\_with\\_Ivermectin\\_and\\_Acetylsalicylic\\_acid\\_of\\_patients\\_with\\_the\\_persistent\\_syndrome\\_of\\_anosmia\\_or\\_hyposmia](https://www.researchgate.net/publication/344468089_COVID-19_Persistent_Treatment_with_Ivermectin_and_Acetylsalicylic_acid_of_patients_with_the_persistent_syndrome_of_anosmia_or_hyposmia)

Babalola, O. et al. Ivermectin shows clinical benefits in mild to moderate Covid19 disease: A randomised controlled double blind dose response study in Lagos.

<https://www.medrxiv.org/content/10.1101/2021.01.05.21249131v1>

Behera, P. et al. Role of ivermectin in the prevention of COVID-19 infection among healthcare workers in India: A matched case-control study.

<https://www.medrxiv.org/content/10.1101/2020.10.29.20222661v1>

Budhiraja, S. et al. Clinical Profile of First 1000 COVID-19 Cases Admitted at Tertiary Care Hospitals and the Correlates of their Mortality: An Indian Experience

<https://www.medrxiv.org/content/10.1101/2020.11.16.20232223v1>

Bukhari, K. et al. Efficacy of Ivermectin in COVID-19 Patients with Mild to Moderate Disease

<https://www.medrxiv.org/content/10.1101/2021.02.02.21250840v1>

Cadegiani, F. A. Early COVID-19 Therapy with Azithromycin Plus Nitazoxanide, Ivermectin or Hydroxychloroquine in Outpatient Settings Significantly Reduced Symptoms Compared to Known Outcomes in Untreated Patients

<https://www.medrxiv.org/content/10.1101/2020.10.31.20223883v1>

Carvalho, H. Safety and Efficacy of the combined use of ivermectin, dexamethasone, enoxaparin and aspirin against COVID-19.

<https://www.medrxiv.org/content/10.1101/2020.09.10.20191619v1>

Chamie-Quintero, J. et al. Sharp Reductions in COVID-19 Case Fatalities and Excess Deaths in Peru in Close Time Conjunction, State-By-State, with Ivermectin Treatments

[https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3765018](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3765018)

Cobos-Campos, R. et al. Potential use of ivermectin for the treatment and profilaxis of SARS-CoV-2 infection: Efficacy of ivermectin for SARS-CoV-2  
<https://www.oatext.com/potential-use-of-ivermectin-for-the-treatment-and-profilaxis-of-sars-cov-2-infection-efficacy-of-ivermectin-for-sars-cov-2.php#Article&gsc.tab=0>

Dias de Melo, G. Anti-COVID-19 efficacy of ivermectin in the golden hamster  
<https://www.biorxiv.org/content/10.1101/2020.11.21.392639v1>

Elgazzer, A. et al. Efficacy and Safety of Ivermectin for Treatment and prophylaxis of COVID-19 Pandemic  
<https://www.researchsquare.com/article/rs-100956/v2>

Frances-Monerris, A. et al. Has Ivermectin Virus-Directed Effects against SARS-CoV-2? Rationalizing the Action of a Potential Multitarget Antiviral Agent  
[https://www.researchgate.net/publication/343563254\\_Has\\_Ivermectin\\_Virus-Directed\\_Effects\\_against\\_SARS-CoV-2\\_Rationalizing\\_the\\_Action\\_of\\_a\\_Potential\\_Multitarget\\_Antiviral\\_Agent](https://www.researchgate.net/publication/343563254_Has_Ivermectin_Virus-Directed_Effects_against_SARS-CoV-2_Rationalizing_the_Action_of_a_Potential_Multitarget_Antiviral_Agent)

Gorial, F.I. et al. Effectiveness of Ivermectin as add-on Therapy in COVID-19 Management (Pilot Trial)  
<https://www.medrxiv.org/content/10.1101/2020.07.07.20145979v1>

Hashim, H.A. et al. Controlled randomized clinical trial on using Ivermectin with Doxycycline for treating COVID-19 patients in Baghdad, Iraq  
<https://www.medrxiv.org/content/10.1101/2020.10.26.20219345v1>

Hill, A. et al. Meta-analysis of randomized trials of ivermectin to treat SARS-CoV-2 infection  
<https://www.researchsquare.com/article/rs-148845/v1>

Jeffreys, L. et al. Remdesivir-Ivermectin combination displays synergistic interaction with improved in vitro antiviral activity against SARS-CoV-2  
<https://www.biorxiv.org/content/10.1101/2020.12.23.424232v1>

Kalfas, S. et al. The Therapeutic Potential of Ivermectin for COVID-19: a systematic review of Mechanisms and Evidience.  
<https://www.medrxiv.org/content/10.1101/2020.11.30.20236570v1.full-text>

Kirty, R. et al. Ivermectin as a potential treatment for mild to moderate COVID-19: A double blind randomized placebo-controlled trial  
<https://www.medrxiv.org/content/10.1101/2021.01.05.21249310v1>

Krolewiecki, A. et al. Antiviral Effect of High-Dose Ivermectin in Adults with COVID-19: A Pilot Randomised, Controlled, Open Label, Multicentre Trial  
[https://papers.ssrn.com/sol3/papers.cfm?abstract\\_id=3714649](https://papers.ssrn.com/sol3/papers.cfm?abstract_id=3714649)

Lawrie, T. Ivermectin reduces the risk of death from COVID-19 -a rapid review and meta-analysis in support of the recommendation of the Front Line COVID-19 Critical Care Alliance.  
[https://www.researchgate.net/publication/348297284\\_Ivermectin\\_reduces\\_the\\_risk\\_of\\_death\\_from\\_COVID-19\\_-a\\_rapid\\_review\\_and\\_meta-analysis\\_in\\_support\\_of\\_the\\_recommendation\\_of\\_the\\_Front\\_Line\\_COVID-19\\_Critical\\_Care\\_Alliance\\_Latest\\_version\\_v12\\_-\\_6\\_Jan\\_2021](https://www.researchgate.net/publication/348297284_Ivermectin_reduces_the_risk_of_death_from_COVID-19_-a_rapid_review_and_meta-analysis_in_support_of_the_recommendation_of_the_Front_Line_COVID-19_Critical_Care_Alliance_Latest_version_v12_-_6_Jan_2021)

Mohan, A. et al. Ivermectin in mild and moderate COVID-19 (RIVET-COV): a randomized, placebo-controlled trial.

[https://www.researchgate.net/publication/348989048\\_Ivermectin\\_in\\_mild\\_and\\_moderate\\_COVID-19\\_RIVET-COV\\_a\\_randomized\\_placebo-controlled\\_trial](https://www.researchgate.net/publication/348989048_Ivermectin_in_mild_and_moderate_COVID-19_RIVET-COV_a_randomized_placebo-controlled_trial)

Morgenstern, J. et al. The use of compassionate Ivermectin in the management of symptomatic outpatients and hospitalized patients with clinical diagnosis of COVID-19 at the Medical Center Bournigal and the Medical Center Punta Cana, Rescue Group, Dominican Republic, from may 1 to august 10, 2020

<https://www.medrxiv.org/content/10.1101/2020.10.29.20222505v1>

Niaee, M.S. et al. Ivermectin as an adjunct treatment for hospitalized adult COVID-19 patients: A randomized multi-center clinical trial

<https://www.researchsquare.com/article/rs-109670/v1>

Soto-Becarra, P. et al. Real-world effectiveness Ivermectin as Pre-exposure Prophylaxis for COVID-19 among Healthcare Providers in a Selected Tertiary Hospital in Dhaka – An Observational Study of hydroxychloroquine, azithromycin, and ivermectin among hospitalized COVID-19 patients: results of a target trial emulation using observational data from a nationwide healthcare system in Peru

<https://www.medrxiv.org/content/10.1101/2020.10.06.20208066v3>

Swargiary, A. Ivermectin as a promising RNA-dependent RNA polymerase inhibitor and a therapeutic drug against SARS-CoV2: Evidence from in silico studies.

<https://www.researchsquare.com/article/rs-73308/v1>

Turkia, M. FLCCC Alliance MATH+ ascorbic acid and I-MASK+ ivermectin protocols for COVID-19 – A Brief Review

[https://www.researchgate.net/publication/345694745\\_FLCCC\\_Alliance\\_MATH\\_ascorbic\\_acid\\_and\\_I-MASK\\_ivermectin\\_protocols\\_for\\_COVID-19\\_-\\_A\\_Brief\\_Review](https://www.researchgate.net/publication/345694745_FLCCC_Alliance_MATH_ascorbic_acid_and_I-MASK_ivermectin_protocols_for_COVID-19_-_A_Brief_Review)

## **Clinical Trials met resultaten**

Chala, R. Prophylaxis Covid-19 in Healthcare Agents by Intensive Treatment With Ivermectin and Iota-carrageenan (Ivercar-Tuc). 2021

[https://www.researchgate.net/publication/345694745\\_FLCCC\\_Alliance\\_MATH\\_ascorbic\\_acid\\_and\\_I-MASK\\_ivermectin\\_protocols\\_for\\_COVID-19\\_-\\_A\\_Brief\\_Review](https://www.researchgate.net/publication/345694745_FLCCC_Alliance_MATH_ascorbic_acid_and_I-MASK_ivermectin_protocols_for_COVID-19_-_A_Brief_Review)

Mahmud, R, Clinical Trial of Ivermectin Plus Doxycycline for the Treatment of Confirmed Covid-19 Infection. 2020

<https://clinicaltrials.gov/ct2/show/results/NCT04523831?view=results>

Okomuş, N. Ivermectin for severe COVID-19 management. 2020

<https://clinicaltrials.gov/ct2/show/NCT04646109>

Raad, H. In vivo use of ivermectin (IVR) for treatment for corona virus infected patients (COVID-19): a randomized controlled trial. 2020

<http://www.chictr.org.cn/showprojen.aspx?proj=54707>

Shouman, W. M. Use of Ivermectin as a Prophylactic Option in Asymptomatic Family Close Contacts with Patients of COVID-19. 2020

[https://clinicaltrials.gov/ProvidedDocs/61/NCT04422561/Prot\\_SAP\\_000.pdf](https://clinicaltrials.gov/ProvidedDocs/61/NCT04422561/Prot_SAP_000.pdf)

## **Review article**

Frediansyah, A. et al. Antivirals for COVID-19: A critical review. *Clinical Epidemiology and Global Health*, 2020; vol. 9: p. 90-98

<https://www.sciencedirect.com/science/article/pii/S2213398420301767>

## **Scientific Letters**

Khan, S. et al. Ivermectin Treatment May Improve the Prognosis of Patients With COVID-19.

*Archivos de Bronconeumología*, 2020; vol. 56 (12): p. 828-830

<https://www.sciencedirect.com/science/article/pii/S030028962030288X>

Pandey, S. et al. Ivermectin in COVID-19: What do we know? *Diabetes & Metabolic Syndrome: Research & Reviews*, 2020; vol. 14 (6): p. 1921-1922

<https://www.sciencedirect.com/science/article/pii/S1871402120303799>

## **Letter to the editor**

Gupta, D. et al. Ivermectin: potential candidate for the treatment of Covid 19. *The Brazilian Journal of Infectious Diseases*, 2020; vol. 24 (4): p. 369 -371

<https://www.bjid.org.br/en-ivermectin-potential-candidate-for-treatment-articulo-S1413867020300817>

DiNicolantonio, J. et al. Ivermectin may be a clinically useful anti-inflammatory agent for late-stage COVID-19. *Open Heart*, 2020; vol. 7(4)

<https://openheart.bmj.com/content/7/2/e001350>

Pena-Silva, R. Pharmacokinetic considerations on the repurposing of ivermectin for treatment of COVID-19. *British Journal of Clinical Pharmacology*. 2020

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7404744/>

Rizzo, E. Ivermectin, Antiviral properties and COVID-19: a possible new mechanism of action.

*Naunyn-Schmiedeberg's Archives of Pharmacology*, 2020; July, 393 (7): p. 1153-1156.

<https://pubmed.ncbi.nlm.nih.gov/32462282/>

Vora, A. et al. White paper on Ivermectin as a potential therapy for COVID-19. *Indian Journal on Tuberculosis*, 2020; vol. 67(3): p.448-451

<https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7434458/>